BidaskClub upgraded shares of OPKO Health (NASDAQ:OPK) from a strong sell rating to a sell rating in a research report sent to investors on Thursday.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded OPKO Health from a hold rating to a sell rating in a report on Friday, February 9th. Cantor Fitzgerald set a $20.00 price objective on OPKO Health and gave the company a buy rating in a report on Thursday, March 1st. JPMorgan Chase downgraded OPKO Health from a neutral rating to an underweight rating and set a $7.00 price objective for the company. in a report on Friday, March 2nd. Finally, ValuEngine downgraded OPKO Health from a sell rating to a strong sell rating in a report on Thursday, March 1st. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $11.29.

Shares of OPK stock opened at $3.08 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.14 and a debt-to-equity ratio of 0.02. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.90.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, March 1st. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). The business had revenue of $193.70 million during the quarter, compared to the consensus estimate of $307.44 million. OPKO Health had a negative return on equity of 7.87% and a negative net margin of 28.93%. research analysts predict that OPKO Health will post -0.48 EPS for the current year.

In related news, Director Robert Scott Fishel purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, April 13th. The stock was acquired at an average price of $3.02 per share, for a total transaction of $30,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Phillip Md Et Al Frost purchased 364,800 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The shares were bought at an average price of $2.94 per share, with a total value of $1,072,512.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $9,022,715.94. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 1,996,365 shares of company stock valued at $7,097,858. Corporate insiders own 40.19% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its holdings in OPKO Health by 7.9% during the second quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,657 shares in the last quarter. Smith Graham & Co. Investment Advisors LP grew its holdings in OPKO Health by 2.0% during the fourth quarter. Smith Graham & Co. Investment Advisors LP now owns 607,102 shares of the biotechnology company’s stock worth $2,975,000 after buying an additional 11,720 shares in the last quarter. Teachers Advisors LLC grew its holdings in OPKO Health by 3.5% during the fourth quarter. Teachers Advisors LLC now owns 489,837 shares of the biotechnology company’s stock worth $2,400,000 after buying an additional 16,675 shares in the last quarter. Legal & General Group Plc grew its holdings in OPKO Health by 17.4% during the third quarter. Legal & General Group Plc now owns 141,535 shares of the biotechnology company’s stock worth $971,000 after buying an additional 21,017 shares in the last quarter. Finally, California Public Employees Retirement System grew its holdings in OPKO Health by 2.8% during the fourth quarter. California Public Employees Retirement System now owns 811,356 shares of the biotechnology company’s stock worth $3,976,000 after buying an additional 22,200 shares in the last quarter. Institutional investors and hedge funds own 23.38% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2018/04/22/opko-health-opk-upgraded-at-bidaskclub.html.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Analyst Recommendations for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.